By Role · Pharma R&D
From Fragmented Trial Signals to Governed Portfolio Intelligence
Maxis AI connected trial risk and evidence-readiness signals to continuous portfolio oversight, accelerating submission preparation by 40-50%
8–12 Wks
Predictive risk forecasting
Scalable
Continuous risk oversight
40–50%
Faster submission prep
50%
Medical writing time reduction
WHO IT IS
The Context
A global CMO / Head of R&D overseeing a multi-program clinical portfolio faced a familiar leadership constraint: trial execution signals were available, but they were fragmented across CROs, systems, and functions.
Enrollment trends, site performance, data quality, safety signals, and submission-readiness indicators were reviewed through periodic reports. By the time risks reached leadership, the practical intervention window had often narrowed.
The pressure was not limited to operational delays. It affected portfolio confidence, evidence quality, regulatory readiness, board reporting, and development decision-making.
The organization needed a governed AI execution layer that could connect risk signals across the clinical lifecycle, support earlier course correction, and improve the path from trial execution to submission readiness.
Challenges
Key barriers to R&D Trial Oversight
Fragmented Trial Signals
- Trial, safety, and quality data were spread across disconnected systems
- Leadership relied on periodic reports
Late Risk Visibility
- Risks were often identified too late for intervention
- Escalation depended on manual coordination
Evidence Confidence Pressure
- Data and validation delays reduced readiness confidence
- Limited visibility into evidence readiness
Submission Readiness Burden
- Regulatory preparation relied on manual document assembly
- Submission gaps were identified late
Operational solution
Maxis AI agentic workflows — under human oversight throughout
Portfolio Risk Intelligence
- Unified trial, safety, and quality signals
- Predictive risks surfaced early
- Faster course correction
Outcome
8–12 weeks predictive risk forecasting
Continuous Oversight
- Continuous monitoring across studies
- Governed risk workflows
- Human validation maintained
Outcome
Scalable continuous risk oversight
Evidence Readiness
- Data quality linked to analysis readiness
- Risks identified earlier
- Teams focused on action
Outcome
Stronger evidence confidence
Maxis AI operates as a governed and supervised execution layer within existing systems throughout.
See it across your portfolio
Curious how this could work across your clinical portfolio?
We'll review your portfolio execution, identify operational bottlenecks, and show where governed AI can improve oversight in a 30-minute working session.
Measured impact
Quantified outcomes after deploying Maxis AI's agentic workflows
| Metric | Before Maxis AI | After Maxis AI |
|---|---|---|
| Portfolio Risk Visibility | Fragmented reporting | Risks surfaced 8–12 weeks earlier |
| Oversight Model | Reactive reviews | Continuous risk oversight |
| Evidence Confidence | Disconnected readiness signals | Improved evidence readiness |
| Submission Preparation | Manual document assembly | 40–50% faster submission prep |
| Medical Writing Burden | Time-intensive drafting | 50% less writing time |
Outcome
Quantified Benefits
R&D leadership moved from delayed, fragmented trial reporting to governed portfolio intelligence across execution, evidence readiness, and submission preparation.
Predictive risk signals surfaced 8–12 weeks in advance
Continuous risk oversight replaced periodic portfolio review dependency
Submission preparation accelerated by 40–50%
Medical writing time reduced by 50%, freeing experts for strategy and content quality
Explore our AI Workforce Platform
See how AI agents are transforming study startup, data management, oversight, and regulatory submissions.